Dr. Carl Joshua Danzig, MD

Dr. Danzig practices at Rand Surgical Pavillion in Pompano Beach, Florida.

Dr. Danzig's NPI, 1619137320, was assigned on June 16, 2008. Dr. Danzig graduated from Lewis Katz School of Medicine in 2004. Dr. Danzig holds Florida license ME109536.

Dr. Danzig's primary practice is Rand Surgical Pavillion, at 5 W Sample Road, Pompano Beach, FL 33064. The practice phone is (954) 782-1700.

Dr. Danzig's primary practice is Rand Surgical Pavillion in Pompano Beach, Florida. Dmand AI also links Dr. Danzig to 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Danzig practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Danzig's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Danzig is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Danzig's licenses on file in 4 states: Florida, Texas, California and Pennsylvania.

Dmand AI lists age-related macular degeneration, cataract, dry eye, eyelid inflammation, glaucoma, hypertensive retinopathy, retinal detachment and retinal occlusion among the conditions Dr. Danzig treats.

CMS data shows 14,174 Medicare services from Dr. Danzig across 15 procedure codes in 2024, for 1,046 Medicare patients. Medicare paid $719,135 for them. Every service was in an office.

CMS counts 1,046 Medicare patients who saw Dr. Danzig in 2024. The largest group is 75 to 84, with 438 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Danzig's median patient age at 75, with 51% women.

In 2024, Dr. Danzig wrote 1,844 Medicare Part D claims for 387 patients. 31% of them were for generic drugs. CMS names the drug for 1,741 of them, across 23 drugs with 11 or more claims each, at $2,620,593 in total drug cost. In 2023, CMS named 1,228 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Danzig for performance year 2024, reported as part of a group. Dr. Danzig accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 22 papers to Dr. Danzig, published from 2021 to 2025. 2023 was the busiest year, with 7. The most frequent topics are Geographic Atrophy, Intravitreal Injections and Angiogenesis Inhibitors. Dr. Danzig has published most often in Ophthalmol Retina. Dr. Danzig's most frequent co-authors are Arshad Mohammad Khanani, MD, Veeral S. Sheth, MD and David Aaron Eichenbaum, MD.

CMS Open Payments shows 557 general payments to Dr. Danzig from 29 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 51% of the total. Genentech, Inc. paid the most, $174,921. It also lists 24 research payments totaling $46,322 from 2020 to 2025.

Dmand AI lists 1 award for Dr. Danzig, most recently CMS Stage 1 EHR in 2014.

Dr. Danzig graduated from Lewis Katz School of Medicine in 2004.

Dr. Danzig is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.